nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.08.2014 | Review Article

Follicular and Scarring Disorders in Skin of Color: Presentation and Management

verfasst von: Pamela Madu, Roopal V. Kundu

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Skin of color, also known as ethnic skin, is described as skin of individuals of African, Asian, Hispanic, Native-American, Middle Eastern, and Pacific Island backgrounds. Differences in hair morphology, hair grooming, cultural practices, and susceptibility to keloid scarring exist within these populations and have been implicated in hair, scalp, and skin disorders. Acne keloidalis (AK), central centrifugal cicatricial alopecia (CCCA), dissecting cellulitis of the scalp (DCS), pseudofolliculitis barbae (PFB), traction alopecia (TA), and keloids are the most prevalent follicular and scarring disorders in skin of color. They have been associated with disfigurement, permanent hair loss, emotional distress, and decreased quality of life. Hair grooming practices, such as the use of chemical relaxers, heat straightening, and tight braiding and weaving can cause scalp irritation and follicular damage and are linked to the pathogenesis of some of these conditions. Consequently, patient education and behavior modifications are integral to the prevention and management of these disorders. Scarring disorders are also of concern in ethnic populations. Keloid scarring is more prevalent in individuals of African, Asian, and Hispanic descent. The scarring alopecia CCCA is almost exclusively seen in patients of African descent. Therapeutic regimens such as intralesional corticosteroids, surgical excision, and laser therapy can be effective for these follicular and scarring disorders, but carry a risk of dyspigmentation and keloid scarring. Ethnic skin and hair may present unique challenges to the clinician, and knowledge of these differences is essential to providing quality care.

Lindelof B, Forslind B, Hedblad MA, Kaveus U. Human hair form. Morphology revealed by light and scanning electron microscopy and computer aided three-dimensional reconstruction. Arch Dermatol. 1988;124(9):1359–63.PubMed

Montagna W, Carlisle K. The architecture of black and white facial skin. J Am Acad Dermatol. 1991;24(6 Pt 1):929–37.PubMed

Vernall DG. A study of the size and shape of cross sections of hair from four races of men. Am J Phys Anthropol. 1961;19:345–50.PubMed

Ackerman AB, Walton NW, Jones RE, Charissi C. Hot comb alopecia/follicular degeneration syndrome in African-American women is traction alopecia. Dermatopathol Prac Concept. 2000:6–21

Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic disease. J Am Acad Dermatol. 2002;46(2 Suppl Understanding):S41–62.PubMed

Chike-Obi CJ, Cole PD, Brissett AE. Keloids: pathogenesis, clinical features, and management. Semin Plast Surg. 2009;23(3):178–84. doi:10.1055/s-0029-1224797.PubMedCentralPubMed

Kaposi M. Pathology and treatment of diseases of the skin for practitioners and students. New York: William Wood and Co; 1895.

Kundu RV, Patterson S. Dermatologic conditions in skin of color: part II. Disorders occurring predominately in skin of color. Am Fam Physician. 2013;87(12):859–65.PubMed

Dinehart SM, Tanner L, Mallory SB, Herzberg AJ. Acne keloidalis in women. Cutis. 1989;44(3):250–2.PubMed

10.

Ogunbiyi A, George A. Acne keloidalis in females: case report and review of literature. J Natl Med Assoc. 2005;97(5):736–8.PubMedCentralPubMed

11.

Kelly AP. Pseudofolliculitis barbae and acne keloidalis nuchae. Dermatol Clin. 2003;21(4):645–53.PubMed

12.

Salami T, Omeife H, Samuel S. Prevalence of acne keloidalis nuchae in Nigerians. Int J Dermatol. 2007;46(5):482–4. doi:10.1111/j.1365-4632.2007.03069.x.PubMed

13.

Sperling LC, Homoky C, Pratt L, Sau P. Acne keloidalis is a form of primary scarring alopecia. Arch Dermatol. 2000;136(4):479–84.PubMed

14.

Herzberg AJ, Dinehart SM, Kerns BJ, Pollack SV. Acne keloidalis. Transverse microscopy, immunohistochemistry, and electron microscopy. Am J Dermatopathol. 1990;12(2):109–21.PubMed

15.

Goette DK, Berger TG. Acne keloidalis nuchae. A transepithelial elimination disorder. Int J Dermatol. 1987;26(7):442–4.PubMed

16.

Khumalo NP, Gumedze F, Lehloenya R. Folliculitis keloidalis nuchae is associated with the risk for bleeding from haircuts. Int J Dermatol. 2011;50(10):1212–6. doi:10.1111/j.1365-4632.2010.04655.x.PubMed

17.

Burkhart CG, Burkhart CN. Acne keloidalis is lichen simplex chronicus with fibrotic keloidal scarring. J Am Acad Dermatol. 1998;39(4 Pt 1):661.PubMed

18.

Koehn GG. Skin injuries in sports medicine. J Am Acad Dermatol. 1991;24(1):152.PubMed

19.

Knable AL Jr, Hanke CW, Gonin R. Prevalence of acne keloidalis nuchae in football players. J Am Acad Dermatol. 1997;37(4):570–4.PubMed

20.

Beckett N, Lawson C, Cohen G. Electrosurgical excision of acne keloidalis nuchae with secondary intention healing. J Clin Aesthet Dermatol. 2011;4(1):36–9.PubMedCentralPubMed

21.

Quarles FN, Brody H, Badreshia S, Vause SE, Brauner G, Breadon JY, et al. Acne keloidalis nuchae. Dermatol Ther. 2007;20(3):128–32. doi:10.1111/j.1529-8019.2007.00123.x.PubMed

22.

Callender VD, Young CM, Haverstock CL, Carroll CL, Feldman SR. An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis. Cutis. 2005;75(6):317–21.PubMed

23.

Esmat SM, Abdel Hay RM, Abu Zeid OM, Hosni HN. The efficacy of laser-assisted hair removal in the treatment of acne keloidalis nuchae; a pilot study. Eur J Dermatol. 2012;22(5):645–50. doi:10.1684/ejd.2012.1830.PubMed

24.

Dragoni F, Bassi A, Cannarozzo G, Bonan P, Moretti S, Campolmi P. Successful treatment of acne keloidalis nuchae resistant to conventional therapy with 1064-nm ND:YAG laser. G Ital Dermatol Venereol. 2013;148(2):231–2.PubMed

25.

Gloster HM Jr. The surgical management of extensive cases of acne keloidalis nuchae. Arch Dermatol. 2000;136(11):1376–9.PubMed

26.

Glenn MJ, Bennett RG, Kelly AP. Acne keloidalis nuchae: treatment with excision and second-intention healing. J Am Acad Dermatol. 1995;33(2 Pt 1):243–6.PubMed

27.

Sperling LC, Skelton HG 3rd, Smith KJ, Sau P, Friedman K. Follicular degeneration syndrome in men. Arch Dermatol. 1994;130(6):763–9.PubMed

28.

LoPresti P, Papa CM, Kligman AM. Hot comb alopecia. Arch Dermatol. 1968;98(3):234–8.PubMed

29.

Sperling LC, Solomon AR, Whiting DA. A new look at scarring alopecia. Arch Dermatol. 2000;136(2):235–42.

30.

Olsen EA, Bergfeld WF, Cotsarelis G, Price VH, Shapiro J, Sinclair R, et al. Summary of North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial Alopecia, Duke University Medical Center, February 10 and 11, 2001. J Am Acad Dermatol. 2003;48(1):103–10. doi:10.1067/mjd.2003.68.PubMed

31.

Halder RM, Grimes PE, McLaurin CI, Kress MA, Kenney JA, Jr. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32(4):388, 390.

32.

Olsen EA, Callender V, McMichael A, Sperling L, Anstrom KJ, Shapiro J, et al. Central hair loss in African American women: incidence and potential risk factors. J Am Acad Dermatol. 2011;64(2):245–52. doi:10.1016/j.jaad.2009.11.693.PubMed

33.

Headington JT. Cicatricial alopecia. Dermatol Clin. 1996;14(4):773–82.PubMed

34.

Nicholson AG, Harland CC, Bull RH, Mortimer PS, Cook MG. Chemically induced cosmetic alopecia. Br J Dermatol. 1993;128(5):537–41.PubMed

35.

Kyei A, Bergfeld WF, Piliang M, Summers P. Medical and environmental risk factors for the development of central centrifugal cicatricial alopecia: a population study. Arch Dermatol. 2011;147(8):909–14. doi:10.1001/archdermatol.2011.66.PubMed

36.

Khumalo NP, Gumedze F. Traction: risk factor or coincidence in central centrifugal cicatricial alopecia? Br J Dermatol. 2012;167(5):1191–3

37.

38.

Dlova NC, Forder M. Central centrifugal cicatricial alopecia: possible familial aetiology in two African families from South Africa. Int J Dermatol. 2012;51(Suppl 1):17–20, 23. doi:10.1111/j.1365-4632.2012.05557.x.

39.

Dlova NC, Jordaan FH, Sarig O, Sprecher E. Autosomal dominant inheritance of central centrifugal cicatricial alopecia in black South Africans. J Am Acad Dermatol. 2014;. doi:10.1016/j.jaad.2013.11.035.

40.

Callender VD, McMichael AJ, Cohen GF. Medical and surgical therapies for alopecias in black women. Dermatol Ther. 2004;17(2):164–76. doi:10.1111/j.1396-0296.2004.04017.x.PubMed

41.

Callender VD, Wright DR, Davis EC, Sperling LC. Hair breakage as a presenting sign of early or occult central centrifugal cicatricial alopecia: clinicopathologic findings in 9 patients. Arch Dermatol. 2012;148(9):1047–52. doi:10.1001/archdermatol.2011.3428.PubMed

42.

Whiting DA, Olsen EA. Central centrifugal cicatricial alopecia. Dermatol Ther. 2008;21(4):268–78. doi:10.1111/j.1529-8019.2008.00209.x.PubMed

43.

Stefanato CM. Histopathology of alopecia: a clinicopathological approach to diagnosis. Histopathology. 2010;56(1):24–38. doi:10.1111/j.1365-2559.2009.03439.x.PubMed

44.

Miteva M, Tosti A. ‘A detective look’ at hair biopsies from African-American patients. Br J Dermatol. 2012;166(6):1289–94. doi:10.1111/j.1365-2133.2012.10892.x.PubMed

45.

Racz E, Gho C, Moorman PW, Noordhoek Hegt V, Neumann HA. Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review. J Eur Acad Dermatol Venereol. 2013;27(12):1461–70. doi:10.1111/jdv.12139.PubMed

46.

Otberg N, Kang H, Alzolibani AA, Shapiro J. Folliculitis decalvans. Dermatol Ther. 2008;21(4):238–44. doi:10.1111/j.1529-8019.2008.00204.x.PubMed

47.

Samrao A, Price VH, Zedek D, Mirmirani P. The “Fringe Sign”—a useful clinical finding in traction alopecia of the marginal hair line. Dermatol Online J. 2011;17(11):1.

48.

Olsen EA. Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective. Journal of Investigative Dermatology Symposium Proceedings/the Society for Investigative Dermatology, Inc [and] European Society for Dermatological Research. 2005;10(3):217-21. doi:10.1111/j.1087-0024.2005.10109.x.

49.

McMichael AJ. Hair and scalp disorders in ethnic populations. Dermatol Clin. 2003;21(4):629–44.PubMed

50.

Chicarilli ZN. Follicular occlusion triad: hidradenitis suppurativa, acne conglobata, and dissecting cellulitis of the scalp. Ann Plast Surg. 1987;18(3):230–7.PubMed

51.

Spitzer L. Dermatitis follicularis et parifollicularis conglobata. Dermatol Ztschr. 1903;10:109

52.

Scott DA. Disorders of the hair and scalp in blacks. Dermatol Clin. 1988;6(3):387–95.PubMed

53.

Stites PC, Boyd AS. Dissecting cellulitis in a white male: a case report and review of the literature. Cutis. 2001;67(1):37–40.PubMed

54.

Lally A, Wojnarowska F. Hypertrophic pseudofolliculitis in white renal transplant recipients. Clin Exp Dermatol. 2007;32(3):268–71. doi:10.1111/j.1365-2230.2007.02386.x.PubMed

55.

Greenblatt DT, Sheth N, Teixeira F. Dissecting cellulitis of the scalp responding to oral quinolones. Clin Exp Dermatol. 2008;33(1):99–100. doi:10.1111/j.1365-2230.2007.02598.x.PubMed

56.

Ramesh V. Dissecting cellulitis of the scalp in 2 girls. Dermatologica. 1990;180(1):48–50.PubMed

57.

Arneja JS, Vashi CN, Gursel E, Lelli JL. Management of fulminant dissecting cellulitis of the scalp in the pediatric population: case report and literature review. Can J Plast Surg. 2007;15(4):211–4.PubMedCentralPubMed

58.

Ramasastry SS, Granick MS, Boyd JB, Futrell JW. Severe perifolliculitis capitis with osteomyelitis. Ann Plast Surg. 1987;18(3):241–4.PubMed

59.

Ongchi DR, Fleming MG, Harris CA. Sternocostoclavicular hyperostosis: two cases with differing dermatologic syndromes. J Rheumatol. 1990;17(10):1415–8.PubMed

60.

Curry SS, Gaither DH, King LE Jr. Squamous cell carcinoma arising in dissecting perifolliculitis of the scalp. A case report and review of secondary squamous cell carcinomas. J Am Acad Dermatol. 1981;4(6):673–8.PubMed

61.

Lim DT, James NM, Hassan S, Khan MA. Spondyloarthritis associated with acne conglobata, hidradenitis suppurativa and dissecting cellulitis of the scalp: a review with illustrative cases. Curr Rheumatol Rep. 2013;15(8). doi:10.1007/s11926-013-0346-y.

62.

Williams CN, Cohen M, Ronan SG, Lewandowski CA. Dissecting cellulitis of the scalp. Plast Reconstr Surg. 1986;77(3):378–82.PubMed

63.

Scheinfeld NS. A case of dissecting cellulitis and a review of the literature. Dermatol Online J. 2003;9(1):8.

64.

Bjellerup M, Wallengren J. Familial perifolliculitis capitis abscedens et suffodiens in two brothers successfully treated with isotretinoin. J Am Acad Dermatol. 1990;23(4 Pt 1):752–3.PubMed

65.

Jacobs F, Metzler G, Kubiak J, Röcken M, Schaller M. New approach in combined therapy of perifolliculitis capitis abscedens et suffodiens. Acta Derm Venereol. 2011;91(6):726–7. doi:10.2340/00015555-1146.PubMed

66.

Stein LL, Adams EG, Holcomb KZ. Inflammatory tinea capitis mimicking dissecting cellulitis in a postpubertal male: a case report and review of the literature. Mycoses. 2013;56(5):596–600. doi:10.1111/myc.12082.PubMed

67.

Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol. 2008;144(6):738–46. doi:10.1001/archderm.144.6.738.PubMed

68.

Annessi G. Tufted folliculitis of the scalp: a distinctive clinicohistological variant of folliculitis decalvans. Br J Dermatol. 1998;138(5):799–805.PubMed

69.

Sperling LC. Scarring alopecia and the dermatopathologist. J Cutan Pathol. 2001;28(7):333–42.PubMed

70.

Branisteanu DE, Molodoi A, Ciobanu D, Badescu A, Stoica LE, Branisteanu D, et al. The importance of histopathologic aspects in the diagnosis of dissecting cellulitis of the scalp. Rom J Morphol Embryol. 2009;50(4):719-24.

71.

Rakowska A, Slowinska M, Kowalska-Oledzka E, Warszawik O, Czuwara J, Olszewska M, et al. Trichoscopy of cicatricial alopecia. J Drugs Dermatol. 2012;11(6):753–8.PubMed

72.

Rodney IJ, Onwudiwe OC, Callender VD, Halder RM. Hair and scalp disorders in ethnic populations. J Drugs Dermatol. 2013;12(4):420–7.PubMed

73.

Khaled A, Zeglaoui F, Zoghlami A, Fazaa B, Kamoun MR. Dissecting cellulitis of the scalp: response to isotretinoin. J Eur Acad Dermatol Venereol. 2007;21(10):1430–1. doi:10.1111/j.1468-3083.2007.02239.x.PubMed

74.

Karpouzis A, Giatromanolaki A, Sivridis E, Kouskoukis C. Perifolliculitis capitis abscedens et suffodiens successfully controlled with topical isotretinoin. Eur J Dermatol. 2003;13(2):192–5.PubMed

75.

Georgala S, Korfitis C, Ioannidou D, Alestas T, Kylafis G, Georgala C. Dissecting cellulitis of the scalp treated with rifampicin and isotretinoin: case reports. Cutis. 2008;82(3):195–8.PubMed

76.

Kobayashi H, Aiba S, Tagami H. Successful treatment of dissecting cellulitis and acne conglobata with oral zinc. Br J Dermatol. 1999;141(6):1137–8.PubMed

77.

Adrian RM, Arndt KA. Perifolliculitis capitis: successful control with alternate-day corticosteroids. Ann Plast Surg. 1980;4(2):166–9.PubMed

78.

Onderdijk AJ, Boer J. Successful treatment of dissecting cellulitis with ciprofloxacin. Clin Exp Dermatol. 2010;35(4):440. doi:10.1111/j.1365-2230.2009.03514.x.

79.

Navarini AA, Trüeb RM. 3 cases of dissecting cellulitis of the scalp treated with adalimumab: control of inflammation within residual structural disease. Arch Dermatol. 2010;146(5):517–20. doi:10.1001/archdermatol.2010.16.PubMed

80.

Sukhatme SV, Lenzy YM, Gottlieb AB. Refractory dissecting cellulitis of the scalp treated with adalimumab. J Drugs Dermatol. 2008;7(10):981–3.PubMed

81.

Brandt HRC, Malheiros APR, Teixeira MG, Machado MCR. Perifolliculitis capitis abscedens et suffodiens successfully controlled with infliximab. Br J Dermatol. 2008;159(2):506–7. doi:10.1111/j.1365-2133.2008.08674.x.PubMed

82.

Boyd AS, Binhlam JQ. Use of an 800-nm pulsed-diode laser in the treatment of recalcitrant dissecting cellulitis of the scalp. Arch Dermatol. 2002;138(10):1291–3.PubMed

83.

Chinnaiyan P, Tena LB, Brenner MJ, Welsh JS. Modern external beam radiation therapy for refractory dissecting cellulitis of the scalp. Br J Dermatol. 2005;152(4):777–9. doi:10.1111/j.1365-2133.2005.06536.x.PubMed

84.

Krasner BD, Hamzavi FH, Murakawa GJ, Hamzavi IH. Dissecting cellulitis treated with the long-pulsed Nd:YAG laser. Dermatol Surg. 2006;32(8):1039–44. doi:10.1111/j.1524-4725.2006.32227.x.PubMed

85.

Scheinfeld NSMD. A case of dissecting cellulitis and a review of the literature. Dermatol Online J. 2003;9(1):8.

86.

Housewright CD, Rensvold E, Tidwell J, Lynch D, Butler DF. Excisional surgery (scalpectomy) for dissecting cellulitis of the scalp. Dermatol Surg. 2011;37(8):1189–91. doi:10.1111/j.1524-4725.2011.02049.x.PubMed

87.

Bellew SG, Nemerofsky R, Schwartz RA, Granick MS. Successful treatment of recalcitrant dissecting cellulitis of the scalp with complete scalp excision and split-thickness skin graft. Dermatol Surg. 2003;29(10):1068–70.PubMed

88.

Kundu RV, Patterson S. Dermatologic conditions in skin of color: part II. Disorders occurring predominately in skin of color. Am Fam Physician. 2013;87(12):859–65.PubMed

89.

Fox H. Observations on skin diseases in the Negro. J Cutan Dis. 1908;26:67–79

90.

Kligman AM, Strauss JS. Pseudofolliculitis of the beard. AMA Arch Dermatol. 1956;74(5):533–42.

91.

Ribera M, Fernandez-Chico N, Casals M. Pseudofolliculitis barbae. Actas Dermo Sifiliograficas. 2010;101(9):749–57.PubMed

92.

Alexander AM, Delph WI. Pseudofolliculitis barbae in the military. A medical, administrative and social problem. J Natl Med Assoc. 1974;66(6):459–64, 79.

93.

Bridgeman S. The medical and surgical therapy of pseudofolliculitis barbae. Dermatol Ther. 2004;17(2):158–63. doi:10.1111/j.1396-0296.2004.04016.x.

94.

Garcia RL, White JW Jr. Pseudofolliculitis barbae in a woman. Arch Dermatol. 1978;114(12):1856.PubMed

95.

Perry PK, Cook-Bolden FE, Rahman Z, Jones E, Taylor SC. Defining pseudofolliculitis barbae in 2001: a review of the literature and current trends. J Am Acad Dermatol. 2002;46(2 Suppl Understanding):S113–9.PubMed

96.

Dunn JF Jr. Pseudofolliculitis barbae. Am Fam Physician. 1988;38(3):169–74.PubMed

97.

Winter H, Schissel D, Parry DAD, Smith TA, Liovic M, Birgitte Lane E et al. An unusual Ala12Thr polymorphism in the 1A alpha-helical segment of the companion layer-specific keratin K6hf: evidence for a risk factor in the etiology of the common hair disorder pseudofolliculitis barbae. J Invest Dermatol. 2004;122(3):652–7. doi:10.1111/j.0022-202X.2004.22309.x.

98.

McLean WHI. Close shave for a keratin disorder-K6hf polymorphism linked to pseudofolliculitis barbae. J Invest Dermatol. 2004;122(3):xi–xiii. doi:10.1111/j.0022-202X.2004.22351.x.

99.

Daniel A, Gustafson CJ, Zupkosky PJ, Candido A, Kemp HR, Russell G, et al. Shave frequency and regimen variation effects on the management of pseudofolliculitis barbae. J Drugs Dermatol. 2013;12(4):410–8.PubMed

100.

Kindred C, Oresajo CO, Yatskayer M, Halder RM. Comparative evaluation of men’s depilatory composition versus razor in black men. Cutis. 2011;88(2):98–103.PubMed

101.

Perricone NV. Treatment of pseudofolliculitis barbae with topical glycolic acid: a report of two studies. Cutis. 1993;52(4):232–5.PubMed

102.

Cook-Bolden FE, Barba A, Halder R, Taylor S. Twice-daily applications of benzoyl peroxide 5%/clindamycin 1% gel versus vehicle in the treatment of pseudofolliculitis barbae. Cutis. 2004;73(6 Suppl):18–24.PubMed

103.

Ross EV, Cooke LM, Timko AL, Overstreet KA, Graham BS, Barnette DJ. Treatment of pseudofolliculitis barbae in skin types IV, V, and VI with a long-pulsed neodymium:yttrium aluminum garnet laser. J Am Acad Dermatol. 2002;47(2):263–70.PubMed

104.

Weaver SM 3rd, Sagaral EC. Treatment of pseudofolliculitis barbae using the long-pulse Nd:YAG laser on skin types V and VI. Dermatol Surg. 2003;29(12):1187–91.PubMed

105.

Battle EF Jr, Hobbs LM. Laser-assisted hair removal for darker skin types. Dermatol Ther. 2004;17(2):177–83. doi:10.1111/j.1396-0296.2004.04018.x.PubMed

106.

Smith EP, Winstanley D, Ross EV. Modified superlong pulse 810 nm diode laser in the treatment of pseudofolliculitis barbae in skin types V and VI. Dermatol Surg. 2005;31(3):297–301

107.

Emer JJ. Best practices and evidenced-based use of the 800 nm diode laser for the treatment of pseudofolliculitis barbae in skin of color. J Drugs Dermatol. 2011;10(12 Suppl):s20–2.PubMed

108.

Xia Y, Cho S, Howard RS, Maggio KL. Topical eflornithine hydrochloride improves the effectiveness of standard laser hair removal for treating pseudofolliculitis barbae: a randomized, double-blinded, placebo-controlled trial. J Am Acad Dermatol. 2012;67(4):694–9. doi:10.1016/j.jaad.2011.10.029.PubMed

109.

Rodney IJ, Onwudiwe OC, Callender VD, Halder RM. Hair and scalp disorders in ethnic populations. J Drugs Dermatol. 2013;12(4):420–7.PubMed

110.

Kanwar AJ, Kaur S, Basak P, Sharma R. Traction alopecia in Sikh males. Arch Dermatol. 1989;125(11):1587.

111.

Hantash BM, Schwartz RA. Traction alopecia in children. Cutis. 2003;71(1):18–20.PubMed

112.

Samrao A, Chen C, Zedek D, Price VH. Traction alopecia in a ballerina: clinicopathologic features. Arch Dermatol. 2010;146(8):930–1. doi:10.1001/archdermatol.2010.183.PubMed

113.

Trüeb RM. “Chignon alopecia”: a distinctive type of nonmarginal traction alopecia. Cutis. 1995;55(3):178–9.PubMed

114.

Karimian-Teherani D, El Shabrawi-Caelen L, Tanew A. Traction alopecia in two adolescent Sikh brothers-an underrecognized problem unmasked by migration. Pediatr Dermatol. 2011;28(3):336–8. doi:10.1111/j.1525-1470.2011.01241.x.PubMed

115.

James J, Saladi RN, Fox JL. Traction alopecia in Sikh male patients. J Am Board Fam Med. 2007;20(5):497–8. doi:10.3122/jabfm.2007.05.070076.PubMed

116.

Rudolph RI, Klein AW, Decherd JW. Corn-row alopecia. Arch Dermatol. 1973;108(1):134.PubMed

117.

Lipnik MJ. Traumatic alopecia from brush rollers. Arch Dermatol. 1961;84:493–5.PubMed

118.

Rucker Wright D, Gathers R, Kapke A, Johnson D, Joseph CLM. Hair care practices and their association with scalp and hair disorders in African American girls. J Am Acad Dermatol. 2011;64(2):253–62. doi:10.1016/j.jaad.2010.05.037.

119.

Khumalo NP, Jessop S, Gumedze F, Ehrlich R. Determinants of marginal traction alopecia in African girls and women. J Am Acad Dermatol. 2008;59(3):432–8. doi:10.1016/j.jaad.2008.05.036.PubMed

120.

Donovan JC, Mirmirani P. Transversely sectioned biopsies in the diagnosis of end-stage traction alopecia. Dermatol Online J. 2013;19(4):11.

121.

Fox GN, Stausmire JM, Mehregan DR. Traction folliculitis: an underreported entity. Cutis. 2007;79(1):26–30.PubMed

122.

Callender VD, McMichael AJ, Cohen GF. Medical and surgical therapies for alopecias in black women. Dermatol Ther. 2004;17(2):164–76. doi:10.1111/j.1396-0296.2004.04017.x.PubMed

123.

Khumalo NP, Ngwanya RM. Traction alopecia: 2 % topical minoxidil shows promise. Report of two cases. J Eur Acad Dermatol Venereol. 2007;21(3):433–4

124.

Ozçelik D. Extensive traction alopecia attributable to ponytail hairstyle and its treatment with hair transplantation. Aesthetic Plast Surg. 2005;29(4):325–7. doi:10.1007/s00266-005-0004-5.PubMed

125.

Naylor MC, Brissett AE. Current concepts in the etiology and treatment of keloids. Facial Plast Surg. 2012;28(5):504–12. doi:10.1055/s-0032-1325644.PubMed

126.

Kelly AP. Medical and surgical therapies for keloids. Dermatol Ther. 2004;17(2):212–8. doi:10.1111/j.1396-0296.2004.04022.x.PubMed

127.

Alhady SM, Sivanantharajah K. Keloids in various races. A review of 175 cases. Plast Reconstr Surg. 1969;44(6):564–6.PubMed

128.

Ramakrishnan KM, Thomas KP, Sundararajan CR. Study of 1,000 patients with keloids in South India. Plast Reconstr Surg. 1974;53(3):276–80.PubMed

129.

Lee TY, Chin GS, Kim WJ, Chau D, Gittes GK, Longaker MT. Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann Plast Surg. 1999;43(2):179–84.PubMed

130.

Marneros AG, Krieg T. Keloids—clinical diagnosis, pathogenesis, and treatment options. J Dtsch Dermatol Ges. 2004;2(11):905–13.PubMed

131.

Saed GM, Ladin D, Olson J, Han X, Hou Z, Fivenson D. Analysis of p53 gene mutations in keloids using polymerase chain reaction-based single-strand conformational polymorphism and DNA sequencing. Arch Dermatol. 1998;134(8):963–7.PubMed

132.

Gao FL, Jin R, Zhang L, Zhang YG. The contribution of melanocytes to pathological scar formation during wound healing. Int J Clin Exp Med. 2013;6(7):609–13.PubMedCentralPubMed

133.

Marneros AG, Norris JE, Olsen BR, Reichenberger E. Clinical genetics of familial keloids. Arch Dermatol. 2001;137(11):1429–34.PubMed

134.

Marneros AG, Norris JE, Watanabe S, Reichenberger E, Olsen BR. Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11. J Invest Dermatol. 2004;122(5):1126–32. doi:10.1111/j.0022-202X.2004.22327.x.PubMed

135.

Yan X, Gao JH, Chen Y, Song M, Liu XJ. [Preliminary linkage analysis and mapping of keloid susceptibility locus in a Chinese pedigree]. Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi =. Chin J Plast Surg. 2007;23(1):32–5.

136.

Bayat A, Arscott G, Ollier WE, Ferguson MW, Mc Grouther DA. Description of site-specific morphology of keloid phenotypes in an Afrocaribbean population. Br J Plast Surg. 2004;57(2):122–33. doi:10.1016/j.bjps.2003.11.009.PubMed

137.

Love PB, Kundu RV. Keloids: an update on medical and surgical treatments. J Drugs Dermatol. 2013;12(4):403–9.PubMed

138.

Nemeth AJ. Keloids and hypertrophic scars. J Dermatol Surg Oncol. 1993;19(8):738–46.PubMed

139.

Juckett G, Hartman-Adams H. Management of keloids and hypertrophic scars. Am Fam Physician. 2009;80(3):253–60.PubMed

140.

Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plast Reconstr Surg. 2010;125(2):557–68. doi:10.1097/PRS.0b013e3181c82dd5.PubMed

141.

Lee JY, Yang CC, Chao SC, Wong TW. Histopathological differential diagnosis of keloid and hypertrophic scar. Am J Dermatopathol. 2004;26(5):379–84.PubMed

142.

Lane JE, Waller JL, Davis LS. Relationship between age of ear piercing and keloid formation. Pediatrics. 2005;115(5):1312–4. doi:10.1542/peds.2004-1085.PubMed

143.

Gold MH, Foster TD, Adair MA, Burlison K, Lewis T. Prevention of hypertrophic scars and keloids by the prophylactic use of topical silicone gel sheets following a surgical procedure in an office setting. Dermatol Surg. 2001;27(7):641–4.PubMed

144.

O’Brien L, Jones DJ. Silicone gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev. 2013;9:CD003826. doi:10.1002/14651858.CD003826.pub3.

145.

Mustoe TA, Cooter RD, Gold MH, Hobbs FD, Ramelet AA, Shakespeare PG, et al. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110(2):560–71.PubMed

146.

Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg. 1999;104(5):1435–58.PubMed

147.

Shepherd JP, Dawber RP. The response of keloid scars to cryosurgery. Plast Reconstr Surg. 1982;70(6):677–82.PubMed

148.

Careta MF, Fortes AC, Messina MC, Maruta CW. Combined treatment of earlobe keloids with shaving, cryosurgery, and intralesional steroid injection: a 1-year follow-up. Dermatol Surg. 2013;39(5):734–8. doi:10.1111/dsu.12107.PubMed

149.

Barara M, Mendiratta V, Chander R. Cryotherapy in treatment of keloids: evaluation of factors affecting treatment outcome. J Cutan Aesthet Surg. 2012;5(3):185–9. doi:10.4103/0974-2077.101376.PubMedCentralPubMed

150.

Layton AM, Yip J, Cunliffe WJ. A comparison of intralesional triamcinolone and cryosurgery in the treatment of acne keloids. Br J Dermatol. 1994;130(4):498–501.PubMed

151.

Weshahy AH. Intralesional cryosurgery. A new technique using cryoneedles. J Dermatol Surg Oncol. 1993;19(2):123–6.PubMed

152.

Malhotra AK, Gupta S, Khaitan BK, Sharma VK. Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids. Dermatology. 2007;215(1):63–5. doi:10.1159/000102036.PubMed

153.

Klumpar DI, Murray JC, Anscher M. Keloids treated with excision followed by radiation therapy. J Am Acad Dermatol. 1994;31(2 Pt 1):225–31.PubMed

154.

Guix B, Henriquez I, Andres A, Finestres F, Tello JI, Martinez A. Treatment of keloids by high-dose-rate brachytherapy: a seven-year study. Int J Radiat Oncol Biol Phys. 2001;50(1):167–72.PubMed

155.

Chen MA, Davidson TM. Scar management: prevention and treatment strategies. Curr Opin Otolaryngol Head Neck Surg. 2005;13(4):242–7.PubMed

156.

Mamalis AD, Lev-Tov H, Nguyen DH, Jagdeo JR. Laser and light-based treatment of Keloids—a review. J Eur Acad Dermatol Venereol. 2013;. doi:10.1111/jdv.12253.PubMed

157.

Norris JE. The effect of carbon dioxide laser surgery on the recurrence of keloids. Plast Reconstr Surg. 1991;87(1):44–9; discussion 50–3.

158.

Garg GA, Sao PP, Khopkar US. Effect of carbon dioxide laser ablation followed by intralesional steroids on keloids. J Cutan Aesthet Surg. 2011;4(1):2–6. doi:10.4103/0974-2077.79176.PubMedCentralPubMed

159.

Alster TS, Williams CM. Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet. 1995;345(8959):1198–200.PubMed

160.

Asilian A, Darougheh A, Shariati F. New combination of triamcinolone, 5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol Surg. 2006;32(7):907–15. doi:10.1111/j.1524-4725.2006.32195.x.PubMed

161.

Shridharani SM, Magarakis M, Manson PN, Singh NK, Basdag B, Rosson GD. The emerging role of antineoplastic agents in the treatment of keloids and hypertrophic scars: a review. Ann Plast Surg. 2010;64(3):355–61. doi:10.1097/SAP.0b013e3181afaab0.PubMed

162.

Uyesugi B, Lippincott B, Dave S. Treatment of a painful keloid with botulinum toxin type A. American journal of physical medicine & rehabilitation/Association of Academic Physiatrists. 2010;89(2):153–5.

163.

Kontochristopoulos G, Stefanaki C, Panagiotopoulos A, Stefanaki K, Argyrakos T, Petridis A, et al. Intralesional 5-fluorouracil in the treatment of keloids: an open clinical and histopathologic study. J Am Acad Dermatol. 2005;52(3 Pt 1):474–9. doi:10.1016/j.jaad.2004.09.018.PubMed

164.

Nanda S, Reddy BS. Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol Surg. 2004;30(1):54–6; discussion 6–7.

165.

Gupta S, Kalra A. Efficacy and safety of intralesional 5-fluorouracil in the treatment of keloids. Dermatology. 2002;204(2):130–2 51830.PubMed

166.

Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol. 2002;138(9):1149–55.PubMed

167.

Aggarwal H, Saxena A, Lubana PS, Mathur RK, Jain DK. Treatment of keloids and hypertrophic scars using bleom. J Cosmet Dermatol. 2008;7(1):43–9. doi:10.1111/j.1473-2165.2008.00360.x.PubMed

168.

Espana A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol Surg. 2001;27(1):23–7.PubMed

169.

Bodokh I, Brun P. Treatment of keloid with intralesional bleomycin. Ann Dermatol Venereol. 1996;123(12):791–4.PubMed

170.

Naeini FF, Najafian J, Ahmadpour K. Bleomycin tattooing as a promising therapeutic modality in large keloids and hypertrophic scars. Dermatol Surg. 2006;32(8):1023–9; discussion 9–30. doi:10.1111/j.1524-4725.2006.32225.x.

Titel: Follicular and Scarring Disorders in Skin of Color: Presentation and Management
verfasst von: Pamela Madu
Roopal V. Kundu
Publikationsdatum: 01.08.2014
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 4/2014
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-014-0072-x

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Metabolic Syndrome Prevalence in Psoriasis

A Practical Approach to Cutaneous Sarcoidosis

Impact of Functional Pruritus Compared with Mild Psoriasis on Quality of Life: A Cross-Sectional Questionnaire Study in Turkey

Low-Power Fractional CO2 Laser Versus Low-Fluence Q-Switch 1,064 nm Nd:YAG Laser for Treatment of Melasma: A Randomized, Controlled, Split-Face Study

A Review of Novel Therapies for Melanoma